Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nexell: Playing to Win or Playing Board Games?

This article was originally published in Start Up

Executive Summary

Nexell failed to take advantage of the financing window for biotech last year, instead opting to establish a $25 million equity line of financing in January 2001. Some observers say its former parent, Baxter, is still calling the shots, including blocking any financing activities that would significantly dilute its investment. How aggressively Nexell draws down the $25 million may serve as an indicator of management's current commitment and belief in itself.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts